Your browser doesn't support javascript.
loading
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
Lau, Sally C M; Perdrizet, Kirstin; Fung, Andrea S; Mata, Danilo Giffoni M M; Weiss, Jessica; Holzapfel, Nick; Liu, Geoffrey; Bradbury, Penelope A; Shepherd, Frances A; Sacher, Adrian G; Feilotter, Harriet; Sheffield, Brandon; Hwang, David; Tsao, Ming Sound; Cheng, Susanna; Cheema, Parneet; Leighl, Natasha B.
Afiliación
  • Lau SCM; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Perdrizet K; Department of Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University (NYU) Langone Health, NYU Grossman School of Medicine, New York, New York.
  • Fung AS; William Osler Health System, Brampton Civic Hospital, Brampton Ontario, Canada.
  • Mata DGMM; Department of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
  • Weiss J; Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Holzapfel N; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Liu G; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Bradbury PA; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Shepherd FA; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Sacher AG; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Feilotter H; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Sheffield B; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Hwang D; Department of Pathology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
  • Tsao MS; William Osler Health System, Brampton Civic Hospital, Brampton Ontario, Canada.
  • Cheng S; Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Cheema P; Department of Pathology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Leighl NB; Department of Medical Oncology, Cancer Centre of Southeastern Ontario, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.
JTO Clin Res Rep ; 4(10): 100562, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37744308
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: JTO Clin Res Rep Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: JTO Clin Res Rep Año: 2023 Tipo del documento: Article País de afiliación: Canadá